• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The tumor suppressor axis p53/miR-34a regulates Axl expression in B-cell chronic lymphocytic leukemia: implications for therapy in p53-defective CLL patients.

作者信息

Boysen J, Sinha S, Price-Troska T, Warner S L, Bearss D J, Viswanatha D, Shanafelt T D, Kay N E, Ghosh A K

机构信息

Division of Hematology, Mayo Clinic, Rochester, MN, USA.

Tolero Pharmaceuticals Inc., Salt Lake City, UT, USA.

出版信息

Leukemia. 2014 Feb;28(2):451-5. doi: 10.1038/leu.2013.298. Epub 2013 Oct 18.

DOI:10.1038/leu.2013.298
PMID:24217154
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3929965/
Abstract
摘要

相似文献

1
The tumor suppressor axis p53/miR-34a regulates Axl expression in B-cell chronic lymphocytic leukemia: implications for therapy in p53-defective CLL patients.肿瘤抑制轴p53/miR-34a调节B细胞慢性淋巴细胞白血病中的Axl表达：对p53缺陷型慢性淋巴细胞白血病患者治疗的意义。
Leukemia. 2014 Feb;28(2):451-5. doi: 10.1038/leu.2013.298. Epub 2013 Oct 18.
2
miR-34a as part of the resistance network in chronic lymphocytic leukemia.微小RNA-34a作为慢性淋巴细胞白血病耐药网络的一部分。
Blood. 2009 Apr 16;113(16):3801-8. doi: 10.1182/blood-2008-08-172254. Epub 2008 Oct 21.
3
Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA.鉴定乳腺癌中的受体酪氨酸激酶 AXL 为人 miR-34a 微 RNA 的靶标。
Breast Cancer Res Treat. 2011 Nov;130(2):663-79. doi: 10.1007/s10549-011-1690-0. Epub 2011 Aug 4.
4
The Axl-Regulating Tumor Suppressor miR-34a Is Increased in ccRCC but Does Not Correlate with Axl mRNA or Axl Protein Levels.调控Axl的肿瘤抑制因子miR-34a在ccRCC中表达增加，但与Axl mRNA或Axl蛋白水平无关。
PLoS One. 2015 Aug 19;10(8):e0135991. doi: 10.1371/journal.pone.0135991. eCollection 2015.
5
Interdependent regulation of p53 and miR-34a in chronic lymphocytic leukemia.慢性淋巴细胞白血病中 p53 和 miR-34a 的相互调控。
Cell Cycle. 2010 Jul 15;9(14):2764-8. Epub 2010 Jul 3.
6
The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy.新型受体酪氨酸激酶 Axl 在 B 细胞慢性淋巴细胞白血病中持续激活，并作为非受体激酶的停靠点发挥作用：对治疗的影响。
Blood. 2011 Feb 10;117(6):1928-37. doi: 10.1182/blood-2010-09-305649. Epub 2010 Dec 6.
7
MiR-34a suppresses ovarian cancer proliferation and motility by targeting AXL.微小RNA-34a通过靶向AXL抑制卵巢癌的增殖和运动能力。
Tumour Biol. 2015 Sep;36(9):7277-83. doi: 10.1007/s13277-015-3445-8. Epub 2015 Apr 21.
8
The BH3-only protein Puma plays an essential role in p53-mediated apoptosis of chronic lymphocytic leukemia cells.BH3 仅蛋白 Puma 在 p53 介导的慢性淋巴细胞白血病细胞凋亡中发挥重要作用。
Leuk Lymphoma. 2013 Dec;54(12):2712-9. doi: 10.3109/10428194.2013.787613. Epub 2013 Apr 30.
9
Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer.miR-34a 和 miR-199a/b 对实体瘤中 Axl 受体酪氨酸激酶表达的调控。
Oncogene. 2011 Jun 23;30(25):2888-99. doi: 10.1038/onc.2011.13. Epub 2011 Feb 14.
10
microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia.miRNA-34a 的表达与慢性淋巴细胞白血病中 MDM2 SNP309 多态性和无治疗生存相关。
Blood. 2010 May 27;115(21):4191-7. doi: 10.1182/blood-2009-07-234823. Epub 2010 Jan 20.

引用本文的文献

1
Proteolysis of TAM receptors in autoimmune diseases and cancer: what does it say to us?自身免疫性疾病和癌症中TAM受体的蛋白水解作用：它向我们传达了什么信息？
Cell Death Dis. 2025 Mar 5;16(1):155. doi: 10.1038/s41419-025-07480-9.
2
Competitive Endogenous RNA Network Involving miRNA and lncRNA in Non-Hodgkin Lymphoma: Current Advances and Clinical Perspectives.非霍奇金淋巴瘤中涉及miRNA和lncRNA的竞争性内源性RNA网络：当前进展与临床展望
Biomedicines. 2021 Dec 17;9(12):1934. doi: 10.3390/biomedicines9121934.
3
Contribution of p53 in sensitivity to EGFR tyrosine kinase inhibitors in non-small cell lung cancer.

本文引用的文献

1
Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA.鉴定乳腺癌中的受体酪氨酸激酶 AXL 为人 miR-34a 微 RNA 的靶标。
Breast Cancer Res Treat. 2011 Nov;130(2):663-79. doi: 10.1007/s10549-011-1690-0. Epub 2011 Aug 4.
2
Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer.miR-34a 和 miR-199a/b 对实体瘤中 Axl 受体酪氨酸激酶表达的调控。
Oncogene. 2011 Jun 23;30(25):2888-99. doi: 10.1038/onc.2011.13. Epub 2011 Feb 14.
3
The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy.
p53 对非小细胞肺癌表皮生长因子受体酪氨酸激酶抑制剂敏感性的影响。
Sci Rep. 2021 Oct 4;11(1):19667. doi: 10.1038/s41598-021-99267-z.
4
SIRT3 overexpression and epigenetic silencing of catalase regulate ROS accumulation in CLL cells activating AXL signaling axis.SIRT3 过表达和过氧化氢酶的表观遗传沉默调节 CLL 细胞中的 ROS 积累，激活 AXL 信号轴。
Blood Cancer J. 2021 May 17;11(5):93. doi: 10.1038/s41408-021-00484-6.
5
The Role of Noncoding RNAs in B-Cell Lymphoma.非编码RNA在B细胞淋巴瘤中的作用。
Front Oncol. 2020 Oct 23;10:577890. doi: 10.3389/fonc.2020.577890. eCollection 2020.
6
AXL Inactivation Inhibits Mesothelioma Growth and Migration via Regulation of p53 Expression.AXL失活通过调节p53表达抑制间皮瘤生长和迁移。
Cancers (Basel). 2020 Sep 25;12(10):2757. doi: 10.3390/cancers12102757.
7
HSP90 overexpression potentiates the B-cell receptor and fibroblast growth factor receptor survival signals in chronic lymphocytic leukemia cells.HSP90过表达增强慢性淋巴细胞白血病细胞中的B细胞受体和成纤维细胞生长因子受体存活信号。
Oncotarget. 2020 Jun 2;11(22):2037-2046. doi: 10.18632/oncotarget.27409.
8
Role of Non-Coding RNAs in the Development of Targeted Therapy and Immunotherapy Approaches for Chronic Lymphocytic Leukemia.非编码RNA在慢性淋巴细胞白血病靶向治疗和免疫治疗方法发展中的作用
J Clin Med. 2020 Feb 21;9(2):593. doi: 10.3390/jcm9020593.
9
AXL Receptor Tyrosine Kinase as a Therapeutic Target in Hematological Malignancies: Focus on Multiple Myeloma.AXL受体酪氨酸激酶作为血液系统恶性肿瘤的治疗靶点：聚焦于多发性骨髓瘤
Cancers (Basel). 2019 Nov 5;11(11):1727. doi: 10.3390/cancers11111727.
10
DS-1205b, a novel selective inhibitor of AXL kinase, blocks resistance to EGFR-tyrosine kinase inhibitors in a non-small cell lung cancer xenograft model.DS-1205b是一种新型AXL激酶选择性抑制剂，在非小细胞肺癌异种移植模型中可阻断对表皮生长因子受体酪氨酸激酶抑制剂的耐药性。
Oncotarget. 2019 Aug 27;10(50):5152-5167. doi: 10.18632/oncotarget.27114.
新型受体酪氨酸激酶 Axl 在 B 细胞慢性淋巴细胞白血病中持续激活，并作为非受体激酶的停靠点发挥作用：对治疗的影响。
Blood. 2011 Feb 10;117(6):1928-37. doi: 10.1182/blood-2010-09-305649. Epub 2010 Dec 6.
4
Epigenetic inactivation of the miR-34a in hematological malignancies.血液恶性肿瘤中 miR-34a 的表观遗传失活。
Carcinogenesis. 2010 Apr;31(4):745-50. doi: 10.1093/carcin/bgq033. Epub 2010 Jan 29.
5
Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.氟达拉滨难治性慢性淋巴细胞白血病（CLL）中p53通路缺陷的详细分析：在前瞻性临床试验中剖析17p缺失、TP53突变、p53-p21功能障碍和miR34a的作用
Blood. 2009 Sep 24;114(13):2589-97. doi: 10.1182/blood-2009-05-224071. Epub 2009 Jul 30.
6
The miR-34 family in cancer and apoptosis.miR-34 家族与癌症和细胞凋亡
Cell Death Differ. 2010 Feb;17(2):193-9. doi: 10.1038/cdd.2009.56. Epub 2009 May 22.
7
miR-34a as part of the resistance network in chronic lymphocytic leukemia.微小RNA-34a作为慢性淋巴细胞白血病耐药网络的一部分。
Blood. 2009 Apr 16;113(16):3801-8. doi: 10.1182/blood-2008-08-172254. Epub 2008 Oct 21.
8
17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation.B淋巴细胞慢性淋巴细胞白血病（B-CLL）患者的17p13/TP53缺失与微小RNA-34a下调有关。
Leukemia. 2009 Mar;23(3):625-7. doi: 10.1038/leu.2008.264. Epub 2008 Sep 25.
9
Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer.多种类型癌症中异常的CpG甲基化导致miR-34a失活。
Cell Cycle. 2008 Aug 15;7(16):2591-600. doi: 10.4161/cc.7.16.6533. Epub 2008 Aug 1.
10
The human receptor tyrosine kinase Axl gene--promoter characterization and regulation of constitutive expression by Sp1, Sp3 and CpG methylation.人类受体酪氨酸激酶Axl基因——启动子特征以及Sp1、Sp3和CpG甲基化对其组成型表达的调控
Biosci Rep. 2008 Jun;28(3):161-76. doi: 10.1042/BSR20080046.